Martin Shkreli is best known for leveraging his time as a hedge fund manager and pharmaceutical entrepreneur into national attention by acquiring rights to the antiparasitic drug Daraprim and sharply raising its price. This profile breaks down his key moves, the 2015 Turing Pharmaceuticals price hike, the SEC and DOJ actions that produced a securities-fraud conviction, ongoing restitution and bans from the industry, and the durable impact on drug pricing debates and public trust. Below, verified details clarify what happened, when, and why it matters.
Early Career and Background
Before the widely publicized events, Shkreli built a trajectory in finance and pharmaceuticals that combined legitimate activity with conduct regulators later deemed criminal. Key steps included education, early roles in finance, forming a hedge fund, and launching a pharmaceutical venture that would draw intense scrutiny.
Education and Entry into Finance
Shkreli attended Baruch College but did not complete a degree. He began his career in finance, taking roles at firms that exposed him to trading, risk, and drug-pricing dynamics. These early experiences informed his later approach to identifying distressed or specialty drugs and repositioning them for niche markets.
Forming a Hedge Fund and Building a Public Profile
He founded a hedge fund that later became embroiled in legal trouble for securities-fraud-like practices involving penny stocks. Concurrently, he cultivated a high-profile, media-facing persona that amplified his visibility well beyond typical finance circles, setting the stage for heightened scrutiny of his subsequent pharmaceutical ventures.
The Turing Pharmaceuticals Acquisition and Price Hike
In 2015, Turing Pharmaceuticals acquired the U.S. marketing rights to Daraprim (pyrimethamine), a decades-old drug used to treat toxoplasmosis and support HIV patients. Shkreli, then CEO, announced a substantial price increase that became the defining controversy of his career and a symbol in debates about drug pricing and ethics.
Acquisition and Immediate Actions
- Acquired U.S. marketing rights for Daraprim in 2015 via Turing Pharmaceuticals.
- Announced a price increase from roughly $13.50 to $750 per tablet overnight.
- Publicly framed the increase as necessary to support further development and compliance, while acknowledging the financial rationale.
Public and Professional Reaction
The move triggered widespread criticism from patients, clinicians, and policymakers. It intensified national conversations about drug affordability and the ethics of pricing life-saving medications. The outcry attracted attention from regulators and the media, leading to congressional hearings and closer examination of Shkreli’s broader business practices.
Securities-Fraud Conviction and Legal Outcomes
Separately from the Turing controversy, Shkreli faced legal action tied to his earlier hedge fund. In 2017, a jury convicted him on multiple counts of securities fraud and conspiracy related to his management of MSMB Capital Management and other investment vehicles. The convictions centered on misleading investors and using illicit means to cover losses.
Trial, Conviction, and Sentencing
| Attribute | Verified Detail | Source Type |
|---|---|---|
| Date of Conviction | March 2017 | Court Record |
| Charges | Securities fraud, conspiracy to commit securities fraud | Indictment and Verdict |
| Sentence | Seven years in federal prison (with time already served and other adjustments) | Court Sentencing Documents |
| Restitution and Penalties | Millions of dollars in restitution and fines, with lifetime industry bans | Court Orders |
Ongoing Obligations and Restrictions
Following release from prison, Shkreli has remained subject to strict conditions, including substantial monetary restitution, prohibitions on working in the securities or pharmaceutical industries, and continuous monitoring by authorities. These ongoing obligations underscore the long-term legal and professional consequences of his actions.
Broader Impacts and Industry Repercussions
The Turing pricing decision and Shkreli’s securities-fraud conviction together reshaped perceptions of pharmaceutical entrepreneurship and investor conduct. They influenced drug-pricing discussions, inspired regulatory proposals, and altered how firms and investors approach reputational and compliance risk.
Drug Pricing and Public Trust
The episode became a case study in drug pricing debates, contributing to policy proposals and increased scrutiny of pharmacy benefit managers and specialty drugs. It also affected public trust in both the pharmaceutical industry and financial managers with biomedical interests.
Compliance and Governance Effects
- Heightened regulatory attention toward pricing and disclosure in drug development.
- Stricter compliance expectations for firms working with high-cost, low-volume medications.
- Investor caution toward figures with outsized public profiles and complex corporate structures.
Status and Current Standing
As of the latest available records, Shkreli remains barred from the pharmaceutical and securities industries, with ongoing financial obligations tied to his restitution and sentencing. He continues to be referenced in discussions about ethics in drug pricing and the responsibilities of corporate leadership.
Verified Points on Current Status
| Attribute | Verified Detail | Source Type |
|---|---|---|
| Industry Bans | Lifetime bans from securities and pharmaceutical sectors | Court Orders |
| Restitution Obligations | Ongoing payments as ordered by the court | Court and Financial Filings |
| Public Presence | Minimal; largely absent from mainstream professional roles | Media and Regulatory Monitoring |
Key Takeaways
- What he did: Acquired Daraprim and raised its price substantially while facing securities-fraud charges tied to earlier investment activities.
- When and how: The 2015 price hike drew immediate backlash; the 2017 conviction addressed distinct securities-fraud allegations. Both events shaped his legal and professional outcomes.
- Why it matters: The case illustrates the intersection of drug pricing, corporate ethics, and securities regulation, and it continues to inform policy and public discourse.